Prevalence Survey and Treatment Regimens for Dyslipidemia in HIV-Infected Adults at a Community Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To study the prevalence and treatment regimens for dyslipidemia, one of the risk factors associated with cardiovascular disease, in HIV-infected adults. Method: A cross-sectional descriptive study was conducted by retrospectively collecting the data from outpatient medical records and computerized database of outpatient departments of HIV-infected adults in KrathumBaen Hospital between January 1st, 2002 and December 31st, 2018. The collected data consisted of patients’ general information, blood lipid profiles, CD4 leukocyte level, antiretroviral drug regimens and treatment regimens of lipid-lowering drugs. Results: From a total of 551 HIV-infected patients, 52.5% were male and average age was 43.4 years. A majority of the patients (75.2%) had received EFV-based regimen. The prevalence of dyslipidemia was 66.8%. High levels of cholesterol, LDL and triglyceride and low levels of HDL were found in 66.6, 63.6, 46.5 and 37.5% of subjects, respectively. 80.3% of the patients had more than two types of abnormal lipid levels. The subjects (58.2%) were treated with lipid-lowering drugs. Most of these patients started the treatment with 600 milligrams of gemfibrozil and the most prevalent recent treatment in 2018 was 300 milligrams of fenofibrate. Lipid-lowering drugs were administered over a total of 80.8 months on average. Conclusions: Prevalence of dyslipidemia in HIV-infected adult patients were 66.8%. Most of them were treated with fibrates alone to control blood lipid levels.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Legarth RA, Ahlstrom MG, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr 2016; 71: 213-8.
Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem AV, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15: 810-8.
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-22.
Abd-Elmoniem KZ, Unsal AB, Eshera S, Matta JR, Muldoon N, McAreavey D, et al. Increased coronary vessel wall thickness in HIV-infected young adults. Clin Infect Dis 2014; 59: 1779-86.
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol 2018; 72: 1141-56.
Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham study. Ann Intern Med 1961; 55: 33-50.
Sritara P, Cheepudomwit S, Chapman N, Woodward M, Kositchaiwat C, Tunlayadechanont S, et al. Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the electricity generating authority of Thailand study. Int J Epidemiol 2003; 32: 461-8.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic) 2007; 6: 36-46.
El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6: 114-21.
Adewole OO, Eze S, Betiku Y, Anteyi E, Wada I, Ajuwon Z, et al. Lipid profile in HIV/AIDS patients in Nigeria. Afr Health Sci 2010; 10: 144-9.
Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2011;57: 141-5.
Shen Y, Wang J, Wang Z, Qi T, Song W, Tang Y, et al. Prevalence of dyslipidemia among antiretroviral-naive HIV-infected individuals in China. Medicine (Baltimore) 2015; 94:e2201. doi:10 .1097/MD.0000000000002201.
Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai 2004; 87: 605-11.
Hiransuthikul N, Hiransuthikul P, Kanasook Y. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Southeast Asian J Trop Med Public Health 2007; 38: 69-77.
Lapphra K, Vanprapar N, Phongsamart W, et al. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 2005; 88: 956-66.
Maina EK, Bonney EY, Bukusi EA, Sedegah M, Lartey M, Ampofo WK. CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies. Immunol Lett 2015; 168: 279-84.
Augustemak de Lima LR, Petroski EL, Moreno YMF, Silva DAS, Trindade EBMS, Carvalho AP, et al. Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The positHIVe health study. PLoS One 2018; 13(1): e0190785. doi:10.1371/journal.pone.0 190785
Bekolo CE, Nguena MB, Ewane L, Bekoule PS, Kollo B. The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population. BMC Public Health 2014; 14: 236. doi: 10.1186/1471-2458-14-236.
Ombeni W, Kamuhabwa AR. Lipid profile in HIV-infected patients using first-line antiretroviral drugs. J Int Assoc Provid AIDS Care 2016; 15: 164-71.
Nampijja D, Kumbakumba E, Bajunirwe F, Kiwanuka J. Dyslipidemia and its correlates among HIV infected children on HAART attending Mbarara regional referral hospital. Int Clin Pathol J 2017; 4: 00098. doi: 10.15406/icpjl.2017.04.00098
Tadesse BT, Foster BA, Chala A, , Chaka TE, Bizuayehu T, Ayalew F, et al. HIV and cART-associated dyslipidemia among HIV-infected child ren. J Clin Med 2019; 8. doi: 10.3390/jcm8040 430.
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012; 18(Suppl 1): 1-78.
Calza L, Colangeli V, Manfredi R, Bon I, Re MC, Viale Pl. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2016; 71: 1451-65.
Jatuporn S, Sangwatanaroj S, Saengsiri Ao, et al. Short‐term effects of an intensive lifestyle modification program on lipid peroxidation and antioxidant systems in patients with coronary artery disease. Clin Hemorheol Microcirc 2003; 29: 429-36.
Ekblom Ö, Ekblom-Bak E, Rosengren A, Hallsten M, Bergström G, Börjesson M. Cardiorespiratory fitness, sedentary behaviour and physical activity are independently associated with the metabolic syndrome, results from the SCAPIS pilot study. PLoS One 2015; 10(6):e0131586. doi:10.1371/journal.pone.0131586.
Wang Z, Wang D, Wang Y. Cigarette smoking and adipose tissue: the emerging role in progression of atherosclerosis. Mediators Inflamm 2017; 2017:310 2737. doi:10.1155/2017/3102737.
Rasheed S, Yan JS, Lau A, Chan AS. HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study. PLoS One 2008; 3: e3003. doi:10.1371/journal.pon e.0003003.
Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep 2016; 13: 218-25.
Jain A, Kolvekar T, Nair DR. HIV infection and lipids. Curr Opin Cardiol 2018; 33: 429-35.
Bowman E, Funderburg NT. Lipidome abnormalities and cardiovascular disease risk in HIV infection. Curr HIV/AIDS Rep 2019; 16: 214-23.
Tesfaye DY, Kinde S, Medhin G, Megerssa YC, Tadewos A, Tadesse E, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr 2014; 8: 102-7.
LE Couteur DG, Cogger VC, McCuskey RS, DE Cabo R, Smedsrød B, Sorensen KK, et al. Age-related changes in the liver sinusoidal endothelium: a mechanism for dyslipidemia. Ann N Y Acad Sci 2007; 1114: 79-87.
van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19. doi:10.1371/journal .pmed.0010019.
Mankhatitham W, Luaengniyomkul A, Manosuthi W. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy. J Med Assoc Thai 2012; 95: 163-9.
Gwag T, Meng Z, Sui Y, Helsley RN, Park SH, Wang S et al. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. J Hepatol 2019; 70: 930-40.
Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol 2015; 115: 1760-6.
Sekhar RV, Balasubramanyam A. Treatment of dyslipidemia in HIV-infected patients. Expert Opin Pharmacother 2010; 11: 1845-54.
Balasubramanyam A, Coraza I, Smith EO, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponec tinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab 2011; 96: 2236-47.
Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asympto matic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses 2013; 29: 547-56.
Stolbach A, Paziana K, Heverling H, Pham P. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol 2015; 11: 326-41.
Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol 2017; 8: 6-14.
Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo R, et al. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretro viral therapy. Pharmacotherapy 2008; 28: 913-9.
